JW Lifescience Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
JW Lifescience has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 4.6% per year. JW Lifescience's return on equity is 16.3%, and it has net margins of 12.4%.
Anahtar bilgiler
1.4%
Kazanç büyüme oranı
2.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 11.3% |
| Gelir büyüme oranı | 4.6% |
| Özkaynak getirisi | 16.3% |
| Net Marj | 12.4% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20
Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Gelir ve Gider Dağılımı
JW Lifescience nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 214,510 | 26,609 | 16,505 | 5,229 |
| 31 Mar 24 | 212,203 | 25,616 | 16,138 | 5,229 |
| 31 Dec 23 | 206,860 | 28,144 | 15,100 | 5,161 |
| 30 Sep 23 | 203,466 | 22,454 | 16,276 | 3,416 |
| 30 Jun 23 | 200,051 | 20,722 | 15,948 | 3,416 |
| 31 Mar 23 | 195,087 | 17,989 | 14,212 | 4,956 |
| 31 Dec 22 | 188,931 | 14,961 | 13,358 | 5,737 |
| 30 Sep 22 | 183,113 | 12,133 | 13,358 | 6,289 |
| 30 Jun 22 | 175,624 | 13,250 | 11,139 | 7,752 |
| 31 Mar 22 | 171,226 | 12,000 | 11,095 | 7,803 |
| 31 Dec 21 | 169,817 | 12,914 | 12,908 | 6,242 |
| 30 Sep 21 | 170,039 | 5,623 | 13,052 | 5,385 |
| 30 Jun 21 | 174,823 | 9,668 | 13,124 | 5,224 |
| 31 Mar 21 | 179,657 | 15,906 | 12,907 | 4,971 |
| 31 Dec 20 | 183,521 | 17,300 | 13,180 | 5,195 |
| 30 Sep 20 | 183,449 | 27,971 | 13,309 | 5,218 |
| 30 Jun 20 | 181,525 | 25,088 | 13,598 | 5,058 |
| 31 Mar 20 | 175,937 | 23,015 | 13,766 | 4,762 |
| 31 Dec 19 | 170,221 | 21,938 | 13,833 | 3,583 |
| 30 Sep 19 | 164,794 | 21,366 | 13,745 | 2,922 |
| 30 Jun 19 | 161,964 | 21,485 | 12,938 | 2,091 |
| 31 Mar 19 | 156,833 | 18,703 | 13,331 | 1,424 |
| 31 Dec 18 | 155,230 | 15,821 | 13,636 | 1,249 |
| 30 Sep 18 | 154,069 | 14,363 | 13,935 | 968 |
| 30 Jun 18 | 151,388 | 13,671 | 13,902 | 730 |
| 31 Mar 18 | 148,331 | 14,997 | 12,893 | 488 |
| 31 Dec 17 | 143,600 | 16,783 | 12,223 | 399 |
| 30 Sep 17 | 139,234 | 16,681 | 11,361 | 524 |
| 30 Jun 17 | 133,223 | 15,922 | 11,449 | 606 |
| 31 Mar 17 | 133,299 | 15,314 | 11,507 | 602 |
| 31 Dec 16 | 132,290 | 15,162 | 11,312 | 665 |
| 30 Sep 16 | 129,096 | 15,416 | 11,852 | 536 |
| 30 Jun 16 | 129,223 | 14,496 | 11,288 | 498 |
| 31 Mar 16 | 127,272 | 14,097 | 10,754 | 454 |
| 31 Dec 15 | 125,950 | 12,864 | 10,535 | 399 |
| 31 Dec 14 | 111,121 | 9,357 | 9,137 | 342 |
| 31 Dec 13 | 88,614 | 1,633 | 7,968 | 396 |
Kaliteli Kazançlar: A234080 has high quality earnings.
Büyüyen Kar Marjı: A234080's current net profit margins (12.4%) are higher than last year (10.4%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A234080's earnings have grown by 1.4% per year over the past 5 years.
Büyüme Hızlandırma: A234080's earnings growth over the past year (28.4%) exceeds its 5-year average (1.4% per year).
Kazançlar vs. Sektör: A234080 earnings growth over the past year (28.4%) exceeded the Pharmaceuticals industry 21.9%.
Özkaynak Getirisi
Yüksek ROE: A234080's Return on Equity (16.3%) is considered low.